Eli Lilly serves up a win over Biden's HHS in drug discount court case
In the battle over a growing federal drug discount program and whether pharma companies can unilaterally change what entities receive certain discounts, the industry was just dealt a win from a US district court.
The Indiana court ruled that a letter from HHS to drugmakers in May, which said their unilateral changes to the discounts were illegal, is “arbitrary and capricious.” Now HRSA, which runs the 340B drug discount program, has to come up with further consideration/action consistent with the opinion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
